Discovery of IRAK4 Inhibitors BAY1834845 (Zabedosertib) and BAY1830839.
Ontology highlight
ABSTRACT: Interleukin-1 receptor-associated kinase 4 (IRAK4) plays a critical role in innate inflammatory processes. Here, we describe the discovery of two clinical candidate IRAK4 inhibitors, BAY1834845 (zabedosertib) and BAY1830839, starting from a high-throughput screening hit derived from Bayer's compound library. By exploiting binding site features distinct to IRAK4 using an in-house docking model, liabilities of the original hit could surprisingly be overcome to confer both candidates with a unique combination of good potency and selectivity. Favorable DMPK profiles and activity in animal inflammation models led to the selection of these two compounds for clinical development in patients.
SUBMITTER: Bothe U
PROVIDER: S-EPMC10823478 | biostudies-literature | 2024 Jan
REPOSITORIES: biostudies-literature
ACCESS DATA